Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow IO Biotech, Inc.

Get SEC filing alerts via email and in your feed for IO Biotech, Inc.

IOBT

IO Biotech, Inc.

About IO Biotech, Inc.

IO Biotech, Inc. is a clinical-stage biopharmaceutical company developing off-the-shelf therapeutic cancer vaccines using its T-win platform. Its products target immunosuppressive tumor microenvironment mechanisms, aiming to activate T cells against cancer cells and suppressive cells. Focused on solid tumors like melanoma, lung, and head and neck cancers, the company seeks to transform cancer immunotherapy through innovative, immune-modulatory vaccines designed for combination treatments and broad patient applicability.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from IO Biotech, Inc.

1
1
IO Biotech, Inc. IO Biotech Reports $8.4 Million Net Loss in Q3 2025, Reduces Operating Expenses by 27%

Via official filing (AI summary) | 7 months ago | 0 comments

2
1
IO Biotech, Inc. IO Biotech Reports $48.6 Million Net Loss and Increased Operating Expenses for First Half of 2025

Via official filing (AI summary) | 10 months ago | 0 comments

3
1
IO Biotech, Inc. IO Biotech Reports $22.4 Million Net Loss in Q1 2025, Increases R&D Spending

Via official filing (AI summary) | about 1 year ago | 0 comments

4
1
IO Biotech, Inc. IO Biotech Reports $95.5 Million Net Loss for 2024, Highlights Clinical Trial Progress

Via official filing (AI summary) | about 1 year ago | 0 comments

5
1
IO Biotech, Inc. IO Biotech Reports Financial Results, Net Loss Increases 10.8% to $24M in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments